Researchers are increasingly interested in the divergent effects of ketamine and psilocybin because these two treatments offer hope for major depressive disorder but work through very different biological systems. A new study helps explain why their therapeutic paths are not the same by examining how each substance alters brainwaves during a controlled auditory task.
This type of research gives clinicians and scientists a clearer view of how these compounds shift neural communication. It also helps identify biomarkers that could guide more precise treatment planning in the future.
How The Study Explored Brainwave Changes
The research team revisited an older EEG dataset that included healthy volunteers who received placebo, S ketamine, or psilocybin during a within subject crossover study. Participants completed an auditory mismatch task, a method commonly used to examine how the brain responds to unexpected sounds. While this paradigm may seem simple, it is highly sensitive to changes in how the brain organizes and filters information.
The team analyzed both the periodic and aperiodic parts of the EEG signal. Periodic activity includes well known rhythms such as alpha and beta waves. Aperiodic activity reflects the overall slope of the EEG signal and can act as an indicator of the balance between excitation and inhibition in the brain.
Because ketamine and psilocybin influence very different receptors, comparing their EEG patterns side by side creates a unique opportunity to understand what sets them apart at a neural level.
What The Researchers Found About Each Substance
The most notable finding was that ketamine produced strong shifts in the aperiodic EEG component. This suggests that ketamine disrupts the usual balance between excitatory and inhibitory signaling in the brain. These changes match earlier work showing that ketamine can mimic some features of early stage psychosis by altering the way neural circuits manage incoming information.
Psilocybin did not show the same aperiodic shift. Instead, its primary changes were tied to oscillatory rhythms. Both psilocybin and ketamine reduced alpha power which is often linked to relaxed wakefulness. However, only ketamine produced a drop in beta activity. Beta rhythms typically support attention and goal directed behavior, which may explain why ketamine produces a more dissociative experience compared to the psychedelic qualities of psilocybin.
Together, these data help clarify why the divergent effects of ketamine and psilocybin matter for clinical practice. Their therapeutic benefits may overlap on the surface, but the way they influence core brain functions is not interchangeable.
Why These Findings Matter For Interventional Psychiatry
Understanding these EEG patterns is valuable for clinicians who want to align treatments with patient needs. Ketamine’s strong effect on aperiodic activity may relate to its rapid but short lived antidepressant action. Psilocybin’s targeted influence on oscillatory rhythms may help explain its longer lasting impact after a single session.
For researchers, these insights support the idea that EEG can serve as a practical biomarker for personalized care. It may eventually be possible to match patients with the treatment that best fits their brain’s unique pattern of activity.
As interventional psychiatry continues to grow, studies like this help build a roadmap for integrating psychedelic assisted therapy and ketamine treatment into evidence based clinical frameworks.
References
- Le GH et al. Spectral signatures of psilocybin, LSD and ketamine in healthy volunteers and depressed patients. Journal of Affective Disorders. 2024. https://doi.org/10.1016/j.jad.2024.03.165
- Anijärv TE et al. Spectral changes of EEG following low dose oral ketamine in adults with depression and suicidality. International Journal of Neuropsychopharmacology. 2023. https://doi.org/10.1093/ijnp/pyad006